Skip to content
TrialScanner

NCT02734290

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Phase 1/Phase 2Active, not recruitingMRKCollaborator

Registry record

Lead sponsor
Providence Health & Services
Conditions
Triple Negative Breast Cancer
Primary completion
Aug 21, 2019Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT02734290 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT02734290: Standard of Care Chemotherapy... | TrialScanner